Contact
searchSearch
HMP Global
Login

Mantle Cell Lymphoma Specialty Channel

Mantle Cell Lymphoma
Specialty Channel
Quiz
Ibrutinib Plus Venetoclax for Patients With TP53-Mutated MCL
10/11/2024
According to results presented at ASCO 2024 from the SYMPATICO study population in patients with MCL with TP53 mutations, the combination of ibrutinib plus venetoclax increased overall survival to ___ months for all 74 patients. 50473230
According to results presented at ASCO 2024 from the SYMPATICO study population in patients with MCL with TP53 mutations, the combination of ibrutinib plus venetoclax increased overall survival to ___ months for all 74 patients. 50473230
According to results presented...
10/11/2024
Oncology
Quiz
FDA Approval of Lisocabtagene Maraleucel for MCL
07/01/2024
07/01/2024
Oncology
FDA Approval
FDA Approves Lisocabtagene Maraleucel for Patients With R/R Mantle Cell Lymphoma
06/03/2024

Amber Denham

Amber Denham
The U.S. Food and Drug Administration granted approval to lisocabtagene maraleucel for adult patients with relapsed or refractory MCL who have received at least 2 prior lines of systemic therapy including a BTK inhibitor.
The U.S. Food and Drug Administration granted approval to lisocabtagene maraleucel for adult patients with relapsed or refractory MCL who have received at least 2 prior lines of systemic therapy including a BTK inhibitor.
The U.S. Food and Drug...
06/03/2024
Oncology
Quiz
Efficacy of Rituximab Maintenance After ASCT Among Patients With Mantle Cell Lymphoma
05/30/2024
05/30/2024
Oncology
News
Rituximab Maintenance After ASCT Yields Long-Term Benefits for Patients With Mantle Cell Lymphoma
03/05/2024

Jordan Kadish

Jordan Kadish
According to a long-term follow-up of the LYMA trial, rituximab maintenance following autologous stem cell transplantation continued to demonstrate benefits to efficacy and safety outcomes among first-line patients with mantle cell lymphoma.
According to a long-term follow-up of the LYMA trial, rituximab maintenance following autologous stem cell transplantation continued to demonstrate benefits to efficacy and safety outcomes among first-line patients with mantle cell lymphoma.
According to a long-term...
03/05/2024
Oncology
News
Novel Prognostic Models Provide Valuable Guidance for Mantle Cell Lymphoma Treatment Strategy
03/01/2024

Jordan Kadish

Jordan Kadish
Advances in prognostic models can help guide treatment strategy for patients with mantle cell lymphoma, according to an analysis by The North American Mantle Cell Lymphoma Consortium.
Advances in prognostic models can help guide treatment strategy for patients with mantle cell lymphoma, according to an analysis by The North American Mantle Cell Lymphoma Consortium.
Advances in prognostic models...
03/01/2024
Oncology
News
BTK Inhibitor and T-Cell Redirecting Immunotherapy Combination Shows Promise for Patients With R/R MCL
02/28/2024

Amber Denham

Amber Denham
According to a phase 2 study, the combination of time-limited ibrutinib and T-cell redirecting immunotherapy demonstrates promising results among patients with relapsed/refractory mantle cell lymphoma.
According to a phase 2 study, the combination of time-limited ibrutinib and T-cell redirecting immunotherapy demonstrates promising results among patients with relapsed/refractory mantle cell lymphoma.
According to a phase 2 study,...
02/28/2024
Oncology
News
MRD-Driven Venetoclax, Lenalidomide, and Rituximab Combo Demonstrates Efficacy Among Patients With R/R Mantle Cell Lymphoma
02/23/2024

Amber Denham

Amber Denham
Minimal residual disease-driven venetoclax, lenalidomide, and rituximab is a feasible and tolerable treatment regimen for patients with relapsed/refractory mantle cell lymphoma, according to results from a phase 1b/2 study.
Minimal residual disease-driven venetoclax, lenalidomide, and rituximab is a feasible and tolerable treatment regimen for patients with relapsed/refractory mantle cell lymphoma, according to results from a phase 1b/2 study.
Minimal residual disease-driven...
02/23/2024
Oncology
Quiz
Efficacy of Rituximab Maintenance Among Elderly Patients With Previously Untreated MCL
02/22/2024
02/22/2024
Oncology
News
MRD Status Predicts Efficacy of Rituximab Maintenance Among Elderly Patients With MCL
01/24/2024
Minimal residual disease status held value in predicting the efficacy of rituximab maintenance among elderly patients with previously untreated mantle cell lymphoma.
Minimal residual disease status held value in predicting the efficacy of rituximab maintenance among elderly patients with previously untreated mantle cell lymphoma.
Minimal residual disease status...
01/24/2024
Oncology
Quiz
Treating R/R Mantle Cell Lymphoma With Orelabrutinib
01/23/2024
According to a multicenter, open-label phase 1/2 study, orelabrutinib demonstrated efficacy and safety among patients with R/R mantle cell lymphoma (MCL), who achieved an overall response rate of ___.
According to a multicenter, open-label phase 1/2 study, orelabrutinib demonstrated efficacy and safety among patients with R/R mantle cell lymphoma (MCL), who achieved an overall response rate of ___.
According to a multicenter,...
01/23/2024
Oncology

News

FDA Approval
FDA Approves Lisocabtagene Maraleucel for Patients With R/R Mantle Cell Lymphoma
06/03/2024

Amber Denham

Amber Denham
The U.S. Food and Drug Administration granted approval to lisocabtagene maraleucel for adult patients with relapsed or refractory MCL who have received at least 2 prior lines of systemic therapy including a BTK inhibitor.
The U.S. Food and Drug Administration granted approval to lisocabtagene maraleucel for adult patients with relapsed or refractory MCL who have received at least 2 prior lines of systemic therapy including a BTK inhibitor.
The U.S. Food and Drug...
06/03/2024
Oncology
News
Rituximab Maintenance After ASCT Yields Long-Term Benefits for Patients With Mantle Cell Lymphoma
03/05/2024

Jordan Kadish

Jordan Kadish
According to a long-term follow-up of the LYMA trial, rituximab maintenance following autologous stem cell transplantation continued to demonstrate benefits to efficacy and safety outcomes among first-line patients with mantle cell lymphoma.
According to a long-term follow-up of the LYMA trial, rituximab maintenance following autologous stem cell transplantation continued to demonstrate benefits to efficacy and safety outcomes among first-line patients with mantle cell lymphoma.
According to a long-term...
03/05/2024
Oncology
News
Novel Prognostic Models Provide Valuable Guidance for Mantle Cell Lymphoma Treatment Strategy
03/01/2024

Jordan Kadish

Jordan Kadish
Advances in prognostic models can help guide treatment strategy for patients with mantle cell lymphoma, according to an analysis by The North American Mantle Cell Lymphoma Consortium.
Advances in prognostic models can help guide treatment strategy for patients with mantle cell lymphoma, according to an analysis by The North American Mantle Cell Lymphoma Consortium.
Advances in prognostic models...
03/01/2024
Oncology
News
BTK Inhibitor and T-Cell Redirecting Immunotherapy Combination Shows Promise for Patients With R/R MCL
02/28/2024

Amber Denham

Amber Denham
According to a phase 2 study, the combination of time-limited ibrutinib and T-cell redirecting immunotherapy demonstrates promising results among patients with relapsed/refractory mantle cell lymphoma.
According to a phase 2 study, the combination of time-limited ibrutinib and T-cell redirecting immunotherapy demonstrates promising results among patients with relapsed/refractory mantle cell lymphoma.
According to a phase 2 study,...
02/28/2024
Oncology
News
MRD-Driven Venetoclax, Lenalidomide, and Rituximab Combo Demonstrates Efficacy Among Patients With R/R Mantle Cell Lymphoma
02/23/2024

Amber Denham

Amber Denham
Minimal residual disease-driven venetoclax, lenalidomide, and rituximab is a feasible and tolerable treatment regimen for patients with relapsed/refractory mantle cell lymphoma, according to results from a phase 1b/2 study.
Minimal residual disease-driven venetoclax, lenalidomide, and rituximab is a feasible and tolerable treatment regimen for patients with relapsed/refractory mantle cell lymphoma, according to results from a phase 1b/2 study.
Minimal residual disease-driven...
02/23/2024
Oncology
News
MRD Status Predicts Efficacy of Rituximab Maintenance Among Elderly Patients With MCL
01/24/2024
Minimal residual disease status held value in predicting the efficacy of rituximab maintenance among elderly patients with previously untreated mantle cell lymphoma.
Minimal residual disease status held value in predicting the efficacy of rituximab maintenance among elderly patients with previously untreated mantle cell lymphoma.
Minimal residual disease status...
01/24/2024
Oncology
News
Rituximab, Lenalidomide, and Ibrutinib Regimen Exhibits Safe and Effective Outcomes Among Patients With R/R MCL
11/28/2023
The R21 regimen, consisting of rituximab, lenalidomide, and ibrutinib, exhibited safe and effective outcomes among patients with R/R mantle cell lymphoma, including those with high-risk features.
The R21 regimen, consisting of rituximab, lenalidomide, and ibrutinib, exhibited safe and effective outcomes among patients with R/R mantle cell lymphoma, including those with high-risk features.
The R21 regimen, consisting of...
11/28/2023
Oncology
News
Brexucabtagene Autoleucel vs Standard-Of-Care Treatment for Patients With R/R MCL
11/28/2023
According to a comparative analysis of the SCHOLAR-2 and ZUMA-2 trials, brexucabtagene autoleucel showed significant survival benefits compared to the standard-of-care treatment for patients with R/R mantle cell lymphoma after covalent BTK...
According to a comparative analysis of the SCHOLAR-2 and ZUMA-2 trials, brexucabtagene autoleucel showed significant survival benefits compared to the standard-of-care treatment for patients with R/R mantle cell lymphoma after covalent BTK...
According to a comparative...
11/28/2023
Oncology
News
Bridging and Salvage Radiotherapy Significantly Improved In-Field Control Among Patients With R/R MCL
11/06/2023
The use of radiotherapy as a bridging and salvage approach significantly improved in-field control outcomes and safety in the peri-CAR T setting among patients with R/R mantle cell lymphoma.
The use of radiotherapy as a bridging and salvage approach significantly improved in-field control outcomes and safety in the peri-CAR T setting among patients with R/R mantle cell lymphoma.
The use of radiotherapy as a...
11/06/2023
Oncology
News
Anti-CD19 CAR T-Cell Therapy Demonstrates Feasibility Among Patients With MCL With Secondary CNS Involvement
11/06/2023
Anti-CD19 chimeric antigen receptor T-cell therapy was demonstrated to be feasible among patients with mantle cell lymphoma with secondary central nervous system involvement.
Anti-CD19 chimeric antigen receptor T-cell therapy was demonstrated to be feasible among patients with mantle cell lymphoma with secondary central nervous system involvement.
Anti-CD19 chimeric antigen...
11/06/2023
Oncology

Interactive Features

Quiz
Ibrutinib Plus Venetoclax for Patients With TP53-Mutated MCL
10/11/2024
According to results presented at ASCO 2024 from the SYMPATICO study population in patients with MCL with TP53 mutations, the combination of ibrutinib plus venetoclax increased overall survival to ___ months for all 74 patients. 50473230
According to results presented at ASCO 2024 from the SYMPATICO study population in patients with MCL with TP53 mutations, the combination of ibrutinib plus venetoclax increased overall survival to ___ months for all 74 patients. 50473230
According to results presented...
10/11/2024
Oncology
Quiz
FDA Approval of Lisocabtagene Maraleucel for MCL
07/01/2024
07/01/2024
Oncology
Quiz
Efficacy of Rituximab Maintenance After ASCT Among Patients With Mantle Cell Lymphoma
05/30/2024
05/30/2024
Oncology
Quiz
Efficacy of Rituximab Maintenance Among Elderly Patients With Previously Untreated MCL
02/22/2024
02/22/2024
Oncology
Quiz
Treating R/R Mantle Cell Lymphoma With Orelabrutinib
01/23/2024
According to a multicenter, open-label phase 1/2 study, orelabrutinib demonstrated efficacy and safety among patients with R/R mantle cell lymphoma (MCL), who achieved an overall response rate of ___.
According to a multicenter, open-label phase 1/2 study, orelabrutinib demonstrated efficacy and safety among patients with R/R mantle cell lymphoma (MCL), who achieved an overall response rate of ___.
According to a multicenter,...
01/23/2024
Oncology
Quiz
Treating MCL With Bridging and Salvage Radiotherapy
12/05/2023
True or False: According to findings from a retrospective study, the use of radiotherapy (RT) as a bridging and salvage approach significantly improved in-field control outcomes, but increased toxicity among patients with relapsed/refractory...
True or False: According to findings from a retrospective study, the use of radiotherapy (RT) as a bridging and salvage approach significantly improved in-field control outcomes, but increased toxicity among patients with relapsed/refractory...
True or False: According to...
12/05/2023
Oncology
Quiz
Anti-CD19 CAR T-Cell Therapy for MCL With SCNS Involvement
12/01/2023
True or False: Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy did not demonstrate feasibility among patients with mantle cell lymphoma (MCL) with secondary central nervous system (SCNS) involvement.
True or False: Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy did not demonstrate feasibility among patients with mantle cell lymphoma (MCL) with secondary central nervous system (SCNS) involvement.
True or False: Anti-CD19...
12/01/2023
Oncology
Quiz
Treating R/R MCL With PI3Kδ Inhibitor Parsaclisib
11/27/2023
True or False: Findings from the phase 2 CITADEL-205 trial indicated that PI3Kδ inhibitor parsaclisib demonstrated significant clinical benefits and a manageable safety profile among patients with R/R mantle cell lymphoma with no prior BTK...
True or False: Findings from the phase 2 CITADEL-205 trial indicated that PI3Kδ inhibitor parsaclisib demonstrated significant clinical benefits and a manageable safety profile among patients with R/R mantle cell lymphoma with no prior BTK...
True or False: Findings from the...
11/27/2023
Oncology
Quiz
Prognostic Value of Single Nucleotide Polymorphism for iNHL and MCL
11/21/2023
Results from a 5-year follow-up study found that gene polymorphisms, particularly the _____ single nucleotide polymorphism (SNP), demonstrated prognostic value for disease outcomes among patients with indolent non-Hodgkin lymphomas and mantle...
Results from a 5-year follow-up study found that gene polymorphisms, particularly the _____ single nucleotide polymorphism (SNP), demonstrated prognostic value for disease outcomes among patients with indolent non-Hodgkin lymphomas and mantle...
Results from a 5-year follow-up...
11/21/2023
Oncology
Quiz
Allogeneic Stem Cell Transplantation for R/R Mantle Cell Lymphoma
11/14/2023
According to findings from an extended follow-up study on allogeneic stem cell transplantation (alloSCT) for R/R mantle cell lymphoma, which of the following statements is true?
According to findings from an extended follow-up study on allogeneic stem cell transplantation (alloSCT) for R/R mantle cell lymphoma, which of the following statements is true?
According to findings from an...
11/14/2023
Oncology

Recent News

FDA Approval
FDA Approves Lisocabtagene Maraleucel for Patients With R/R Mantle Cell Lymphoma
06/03/2024

Amber Denham

Amber Denham
The U.S. Food and Drug Administration granted approval to lisocabtagene maraleucel for adult patients with relapsed or refractory MCL who have received at least 2 prior lines of systemic therapy including a BTK inhibitor.
The U.S. Food and Drug Administration granted approval to lisocabtagene maraleucel for adult patients with relapsed or refractory MCL who have received at least 2 prior lines of systemic therapy including a BTK inhibitor.
The U.S. Food and Drug...
06/03/2024
Oncology
News
Rituximab Maintenance After ASCT Yields Long-Term Benefits for Patients With Mantle Cell Lymphoma
03/05/2024

Jordan Kadish

Jordan Kadish
According to a long-term follow-up of the LYMA trial, rituximab maintenance following autologous stem cell transplantation continued to demonstrate benefits to efficacy and safety outcomes among first-line patients with mantle cell lymphoma.
According to a long-term follow-up of the LYMA trial, rituximab maintenance following autologous stem cell transplantation continued to demonstrate benefits to efficacy and safety outcomes among first-line patients with mantle cell lymphoma.
According to a long-term...
03/05/2024
Oncology
News
Novel Prognostic Models Provide Valuable Guidance for Mantle Cell Lymphoma Treatment Strategy
03/01/2024

Jordan Kadish

Jordan Kadish
Advances in prognostic models can help guide treatment strategy for patients with mantle cell lymphoma, according to an analysis by The North American Mantle Cell Lymphoma Consortium.
Advances in prognostic models can help guide treatment strategy for patients with mantle cell lymphoma, according to an analysis by The North American Mantle Cell Lymphoma Consortium.
Advances in prognostic models...
03/01/2024
Oncology
News
BTK Inhibitor and T-Cell Redirecting Immunotherapy Combination Shows Promise for Patients With R/R MCL
02/28/2024

Amber Denham

Amber Denham
According to a phase 2 study, the combination of time-limited ibrutinib and T-cell redirecting immunotherapy demonstrates promising results among patients with relapsed/refractory mantle cell lymphoma.
According to a phase 2 study, the combination of time-limited ibrutinib and T-cell redirecting immunotherapy demonstrates promising results among patients with relapsed/refractory mantle cell lymphoma.
According to a phase 2 study,...
02/28/2024
Oncology
News
MRD-Driven Venetoclax, Lenalidomide, and Rituximab Combo Demonstrates Efficacy Among Patients With R/R Mantle Cell Lymphoma
02/23/2024

Amber Denham

Amber Denham
Minimal residual disease-driven venetoclax, lenalidomide, and rituximab is a feasible and tolerable treatment regimen for patients with relapsed/refractory mantle cell lymphoma, according to results from a phase 1b/2 study.
Minimal residual disease-driven venetoclax, lenalidomide, and rituximab is a feasible and tolerable treatment regimen for patients with relapsed/refractory mantle cell lymphoma, according to results from a phase 1b/2 study.
Minimal residual disease-driven...
02/23/2024
Oncology
News
MRD Status Predicts Efficacy of Rituximab Maintenance Among Elderly Patients With MCL
01/24/2024
Minimal residual disease status held value in predicting the efficacy of rituximab maintenance among elderly patients with previously untreated mantle cell lymphoma.
Minimal residual disease status held value in predicting the efficacy of rituximab maintenance among elderly patients with previously untreated mantle cell lymphoma.
Minimal residual disease status...
01/24/2024
Oncology
News
Rituximab, Lenalidomide, and Ibrutinib Regimen Exhibits Safe and Effective Outcomes Among Patients With R/R MCL
11/28/2023
The R21 regimen, consisting of rituximab, lenalidomide, and ibrutinib, exhibited safe and effective outcomes among patients with R/R mantle cell lymphoma, including those with high-risk features.
The R21 regimen, consisting of rituximab, lenalidomide, and ibrutinib, exhibited safe and effective outcomes among patients with R/R mantle cell lymphoma, including those with high-risk features.
The R21 regimen, consisting of...
11/28/2023
Oncology
News
Brexucabtagene Autoleucel vs Standard-Of-Care Treatment for Patients With R/R MCL
11/28/2023
According to a comparative analysis of the SCHOLAR-2 and ZUMA-2 trials, brexucabtagene autoleucel showed significant survival benefits compared to the standard-of-care treatment for patients with R/R mantle cell lymphoma after covalent BTK...
According to a comparative analysis of the SCHOLAR-2 and ZUMA-2 trials, brexucabtagene autoleucel showed significant survival benefits compared to the standard-of-care treatment for patients with R/R mantle cell lymphoma after covalent BTK...
According to a comparative...
11/28/2023
Oncology
News
Bridging and Salvage Radiotherapy Significantly Improved In-Field Control Among Patients With R/R MCL
11/06/2023
The use of radiotherapy as a bridging and salvage approach significantly improved in-field control outcomes and safety in the peri-CAR T setting among patients with R/R mantle cell lymphoma.
The use of radiotherapy as a bridging and salvage approach significantly improved in-field control outcomes and safety in the peri-CAR T setting among patients with R/R mantle cell lymphoma.
The use of radiotherapy as a...
11/06/2023
Oncology
News
Anti-CD19 CAR T-Cell Therapy Demonstrates Feasibility Among Patients With MCL With Secondary CNS Involvement
11/06/2023
Anti-CD19 chimeric antigen receptor T-cell therapy was demonstrated to be feasible among patients with mantle cell lymphoma with secondary central nervous system involvement.
Anti-CD19 chimeric antigen receptor T-cell therapy was demonstrated to be feasible among patients with mantle cell lymphoma with secondary central nervous system involvement.
Anti-CD19 chimeric antigen...
11/06/2023
Oncology
News
Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer
11/14/2024
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective...
11/14/2024
Oncology
News
Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer
11/14/2024
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the...
11/14/2024
Oncology
News
Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma
11/13/2024
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2...
11/13/2024
Oncology
News
Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
11/12/2024
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial,...
11/12/2024
Oncology
News
Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer
11/12/2024
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from...
11/12/2024
Oncology
News
Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer
11/11/2024
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a...
11/11/2024
Oncology
FDA Approval
FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia
11/08/2024
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA...
11/08/2024
Oncology
News
Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer
11/07/2024
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus...
11/07/2024
Oncology
News
Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
11/06/2024
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a...
11/06/2024
Oncology
News
Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma
11/05/2024
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study...
11/05/2024
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use